149 related articles for article (PubMed ID: 37422450)
1. The ELK3-DRP1 axis determines the chemosensitivity of triple-negative breast cancer cells to CDDP by regulating mitochondrial dynamics.
Park JD; Jang HJ; Choi SH; Jo GH; Choi JH; Hwang S; Park W; Park KS
Cell Death Discov; 2023 Jul; 9(1):237. PubMed ID: 37422450
[TBL] [Abstract][Full Text] [Related]
2. ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics.
Park JD; Kim KS; Choi SH; Jo GH; Choi JH; Park SW; Ko ES; Lee M; Lee DK; Jang HJ; Hwang S; Jung HY; Park KS
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858708
[TBL] [Abstract][Full Text] [Related]
3. ELK3-ID4 axis governs the metastatic features of triple negative breast cancer.
Choi JH; Park JD; Choi SH; Ko ES; Jang HJ; Park KS
Oncol Res; 2023; 32(1):127-138. PubMed ID: 38188675
[TBL] [Abstract][Full Text] [Related]
4. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine.
Hu J; Zhang Y; Jiang X; Zhang H; Gao Z; Li Y; Fu R; Li L; Li J; Cui H; Gao N
J Exp Clin Cancer Res; 2019 May; 38(1):225. PubMed ID: 31138329
[TBL] [Abstract][Full Text] [Related]
5. ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer.
Jung HY; Lee DK; Lee M; Choi SH; Park JD; Ko ES; Lee J; Park KS; Jung HY
Oncoimmunology; 2023; 12(1):2190671. PubMed ID: 36950218
[TBL] [Abstract][Full Text] [Related]
6. Functional Link between miR-200a and ELK3 Regulates the Metastatic Nature of Breast Cancer.
Kim HK; Park JD; Choi SH; Shin DJ; Hwang S; Jung HY; Park KS
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414208
[TBL] [Abstract][Full Text] [Related]
7. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
8. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis.
Al-Bahlani S; Al-Lawati H; Al-Adawi M; Al-Abri N; Al-Dhahli B; Al-Adawi K
Apoptosis; 2017 Jun; 22(6):865-876. PubMed ID: 28386750
[TBL] [Abstract][Full Text] [Related]
10. SMAD3 promotes ELK3 expression following transforming growth factor β-mediated stimulation of MDA-MB231 cells.
Park JH; Park KS
Oncol Lett; 2020 Apr; 19(4):2749-2754. PubMed ID: 32218827
[TBL] [Abstract][Full Text] [Related]
11. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
12. Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.
Tzeng YT; Liu PF; Li JY; Liu LF; Kuo SY; Hsieh CW; Lee CH; Wu CH; Hsiao M; Chang HT; Shu CW
Front Pharmacol; 2018; 9():1285. PubMed ID: 30473665
[No Abstract] [Full Text] [Related]
13. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
14. ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes.
Kim KS; Kim J; Oh N; Kim MY; Park KS
Biochem Biophys Res Commun; 2018 Apr; 498(3):509-515. PubMed ID: 29510139
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy.
Park JH; Kim KP; Ko JJ; Park KS
Biochem Biophys Res Commun; 2016 Aug; 477(2):277-82. PubMed ID: 27301639
[TBL] [Abstract][Full Text] [Related]
16. ZEB1 Collaborates with ELK3 to Repress E-Cadherin Expression in Triple-Negative Breast Cancer Cells.
Cho HJ; Oh N; Park JH; Kim KS; Kim HK; Lee E; Hwang S; Kim SJ; Park KS
Mol Cancer Res; 2019 Nov; 17(11):2257-2266. PubMed ID: 31511359
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-Mediated Mitochondrial Dysfunction Is Involved in the Anti-triple-Negative Breast Cancer Cell Activity of Phytosesquiterpene Lactones.
Cheng YT; Nakagawa-Goto K; Lee KH; Shyur LF
Antioxid Redox Signal; 2023 Jan; 38(1-3):198-214. PubMed ID: 35850524
[No Abstract] [Full Text] [Related]
19. Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells.
Chen L; Zhang J; Lyu Z; Chen Y; Ji X; Cao H; Jin M; Zhu J; Yang J; Ling R; Xing J; Ren T; Lyu Y
Cell Death Dis; 2018 Oct; 9(11):1050. PubMed ID: 30323195
[TBL] [Abstract][Full Text] [Related]
20. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
